Tiziana Life Sciences (TLSA) Receivables (2017 - 2022)

Tiziana Life Sciences (TLSA) has reported Receivables for 6 consecutive years, with $4.8 million the latest figure, recorded in Q4 2022.

• Quarterly Receivables rose 175.81% year-over-year to $4.8 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $4.8 million (up 175.81% YoY) and the FY2022 annual result came in at $4.8 million, up 175.81% from the prior year.
• Receivables improved to $4.8 million in Q4 2022 per TLSA's latest filing, from $1.8 million in the prior quarter.
• Over the last five years, Receivables for TLSA reached as high as $4.8 million in Q4 2022 and fell as low as $72204.8 in Q2 2018.
• A 5-year average of $1.5 million and a median of $897855.9 in 2020 frame the typical range for Receivables.
• Annual changes were most pronounced in 2018 — Receivables slumped 86.91% — and 2020, when it jumped 693.13%.
• Year by year, Receivables stood at $319118.3 in 2018, then jumped by 92.59% to $614576.5 in 2019, then surged by 92.19% to $1.2 million in 2020, then soared by 48.76% to $1.8 million in 2021, then jumped by 175.81% to $4.8 million in 2022.
• According to Business Quant data, Receivables over the past three periods registered $4.8 million, $1.8 million, and $1.2 million for Q4 2022, Q4 2021, and Q4 2020 respectively.